PMC:7696151 / 115376-116001 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"4098","span":{"begin":119,"end":127},"obj":"Species"},{"id":"4099","span":{"begin":408,"end":416},"obj":"Species"},{"id":"4212","span":{"begin":147,"end":155},"obj":"Disease"},{"id":"4213","span":{"begin":399,"end":407},"obj":"Disease"},{"id":"4214","span":{"begin":599,"end":624},"obj":"Disease"}],"attributes":[{"id":"A4098","pred":"tao:has_database_id","subj":"4098","obj":"Tax:9606"},{"id":"A4099","pred":"tao:has_database_id","subj":"4099","obj":"Tax:9606"},{"id":"A4212","pred":"tao:has_database_id","subj":"4212","obj":"MESH:C000657245"},{"id":"A4213","pred":"tao:has_database_id","subj":"4213","obj":"MESH:C000657245"},{"id":"A4214","pred":"tao:has_database_id","subj":"4214","obj":"MESH:D012817"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Skipper, et al. (2020) [37] Randomized, double-blind, placebo-controlled trial491 symptomatic, non-hospitalized adult patients with early or mild COVID-19 HCQ group -\u003e HCQ 800 mg once, followed by 600 mg in 6 to 8 h, then 600 mg daily for 4 more daysControl group-\u003e masked placebo14 weeks of treatment HCQ did not reduce symptom severity when compared with placebo in non-hospitalized early/mild COVID-19 patients (difference in symptom severity: relative, 12%; absolute, −0.27 points (95% CI, −0.61 to 0.07 points); p = 0.117) With HCQ, the most commonly reported adverse effect was related to gastrointestinal symptoms:"}

{"project":"LitCovid-sentences","denotations":[{"id":"T773","span":{"begin":0,"end":625},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Skipper, et al. (2020) [37] Randomized, double-blind, placebo-controlled trial491 symptomatic, non-hospitalized adult patients with early or mild COVID-19 HCQ group -\u003e HCQ 800 mg once, followed by 600 mg in 6 to 8 h, then 600 mg daily for 4 more daysControl group-\u003e masked placebo14 weeks of treatment HCQ did not reduce symptom severity when compared with placebo in non-hospitalized early/mild COVID-19 patients (difference in symptom severity: relative, 12%; absolute, −0.27 points (95% CI, −0.61 to 0.07 points); p = 0.117) With HCQ, the most commonly reported adverse effect was related to gastrointestinal symptoms:"}